EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial

Laura M Güdemann iD, Catherine Angwin, Rury R Holman, Naveed Sattar iD, Ewan R Pearson, Jacques Murray Leech, Kashyap A Patel, Andrew T Hattersley iD, John M Dennis, Beverley M Shields, Angus G Jones iD

Diabetes Care · 2026

DOI: 10.2337/dc26-0118 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2026. Verfasst von Laura M Güdemann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, U.K. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: European Association for the Study of Diabetes (EFSD), Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Different precision treatment approaches have been proposed for type 2 diabetes, but robust comparisons are lacking. We compared the utility of proposed approaches targeting glucose-lowering therapy in the TriMaster three-way crossover trial. RESEARCH DESIGN AND METHODS We evaluated four previously reported precision treatment strategies for their ability to predict overall 4-month HbA1c response and within-person differential response to sitagliptin, canagliflozin, and pioglitazone in 309 adults with type 2 diabetes who received all three medications. Approaches included allocation to clusters based on routine features and HOMA, direct outcome prediction using a routine-features treatment-selection model, type 2 diabetes cluster-specific partitioned polygenic scores (PPSs), and a model based on discriminative dimensionality reduction tree (DDRTree) analysis. RESULTS The routine-features model and cluster approach were both strongly associated with overall and differential HbA1c responses (P < 0.0001). The routine-features model identified the most effective therapy with significant benefit across all drug comparisons, whereas clinical clusters showed benefit for only one cluster-drug comparison (severe insulin-resistant diabetes: SGLT2i vs. thiazolidinedione [TZD], P = 0.005). DDRTree was not associated with treatment response. Of eight PPSs, only two showed modest association with differential response (lipodystrophy PPS had a greater response to SGLT2 vs. TZD; and β-cell dysfunction, negative proinsulin PPS had a greater response to TZD vs. dipeptidyl peptidase 4 inhibitor). Treatment allocation based on the routine-features model resulted in greater HbA1c reduction than cluster-based allocation (0.27% [95% CI 0.18, 0.35], 2.9 mmol/mol [95% CI 2.0, 3.8] vs. 0.16% [95% CI 0.07, 0.25], 1.7 mmol/mol [95% CI 0.8, 2.7]). CONCLUSIONS Clinical features are more strongly associated with differential glycemic response than PPS, and direct outcome prediction outperforms data-driven subgrouping for optimizing short-term HbA1c reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsHumansGlycated HemoglobinCross-Over StudiesSitagliptin PhosphatePioglitazoneCanagliflozinFemaleMaleMiddle AgedThiazolidinedionesPPAR-gamma AgonistsBlood GlucoseTreatment Effect HeterogeneityClustering Algorithms

Substanzen

Hypoglycemic AgentsGlycated HemoglobinSitagliptin PhosphatePioglitazoneCanagliflozinThiazolidinedionesPPAR-gamma AgonistsBlood Glucose

Autor:innen und Institutionen

  • Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, U.K.
  • Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K.
  • National Institute for Health and Care Research Oxford Biomedical Research Centre, Churchill Hospital, Oxford, U.K.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, U.K.
  • Division of Diabetes, Endocrinology and Reproductive Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, U.K.

ORCID-Profile: Laura M Güdemann, Naveed Sattar, Andrew T Hattersley, Angus G Jones

Förderung

  • European Association for the Study of Diabetes (EFSD)
  • Novo Nordisk Foundation

Zitieren

APA

Güdemann, L. M., Angwin, C., Holman, R. R., Sattar, N., Pearson, E. R., Murray Leech, J., Patel, K. A., Hattersley, A. T., Dennis, J. M., Shields, B. M., & Jones, A. G. (2026). To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial. Diabetes Care. https://doi.org/10.2337/dc26-0118

Vancouver

Güdemann LM, Angwin C, Holman RR, Sattar N, Pearson ER, Murray Leech J, et al. To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial. Diabetes Care. 2026. doi:10.2337/dc26-0118

BibTeX
@article{Gdemann2026,
  author = {Güdemann, Laura M and Angwin, Catherine and Holman, Rury R and Sattar, Naveed and Pearson, Ewan R and Murray Leech, Jacques and Patel, Kashyap A and Hattersley, Andrew T and Dennis, John M and Shields, Beverley M and Jones, Angus G},
  title = {To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial},
  journal = {Diabetes Care},
  year = {2026},
  doi = {10.2337/dc26-0118}
}
Kostenlos starten →